Overall CDKN2A/B deletion was rare, present in only 108 of 1506 patients (7.1%, excluding the IHC cohort), even though several of the cohorts we included were enriched for clinically aggressive meningiomas with early recurrences (Fig. 1a). The gene discussed is CDKN2A; the disease is meningioma.